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ABSTRACT
Objective: This study aimed to measure metformin levels and evaluates the incurred stability in plasma of six healthy subjects after administration 
850 mg metformin hydrochloride tablet using high-performance liquid chromatography.
Methods: Samples were collected from six healthy subjects who were administered 850 mg metformin hydrochloride tablet. Blood was collected from 
the subjects at up to 12-time points throughout a 12 h period. Sample stability was analyzed on days 7, 14, and 30. The analysis was conducted using 
C-18 columns, a column temperature of 40°C, a mobile phase consisting of acetonitrile-phosphate buffer (pH 7.0; 40:60 v/v), a flow rate of 1 mL/min, 
the photodiode array detector set at a wavelength of 234 nm, and calcium atorvastatin as the internal standard.
Results: All metformin HCl samples collected on days 7, 14, and 30 from subjects 1 to 6 met stability requirement based on the European Medicines 
Agency Bioanalytical Guideline (2011), which state that the percentage difference value not >20%. In addition, the developed method for analyzing 
metformin HCl in plasma was linear in the concentration range of 20.0–5000.0 ng/mL (r=0.9999).
Conclusion: The incurred sample of metformin hydrochloride in plasma of six healthy subjects was stable until 30 days after drug administration.
Keywords: High-performance liquid chromatography, Human plasma, Incurred sample, Metformin hydrochloride, Partial validation.
INTRODUCTION
Metformin is an oral antidiabetes drug belonging to the biguanide class. 
Indeed, metformin is the first drug of choice for adults newly diagnosed 
with type 2 diabetes, particularly for those people who are overweight 
or obese. The mechanism of action of metformin consists of lowering 
blood sugar levels by decreasing the production of hepatic sugars and 
reducing the absorption of glucose in the small intestine. In addition, 
metformin serves to maintain blood glucose levels in peripheral tissues, 
particularly after meals and has antilipolytic effects that decrease serum 
free fatty acid concentrations, thereby reducing substrate availability 
for glycogenesis [1-4].
Metformin is considered a critical-use drug, which includes drugs 
for serious conditions that require a definite response. The study 
of the pharmacokinetics of metformin has included a series of 
tests to determine certain pharmacokinetics parameters [5,6]. This 
pharmacokinetic test data can then be used to assess the rate of change 
or the degree of availability between formulations (i.e., bioequivalence 
[BE]). However, before performing pharmacokinetic studies, it is 
necessary to validate the bioanalysis method for the drug. In this 
process, one of the parameters of interest is the incurred sample 
reanalysis (ISR) [7,8].
The assessment of recurrent levels of study samples as part of the 
ISR has the purpose of evaluating the reproducibility of the results 
of bioanalysis tests. As such, ISR is considered routine practice in 
bioanalysis, which is a requirement based on regulations and guidelines 
concerning the validation of bioanalytical methods, including those 
stipulated by the European Medicines Agency and the Food and Drug 
Administration. Specifically, the incurred sample stability is a reanalysis 
of some incurred samples over a period of time to determine whether the 
analyte is stable and present in reproducible analytical concentrations. 
In general, analyte stability can be assessed by measuring in vitro QC 
samples known to be concentrated at a given time. However, in some 
cases, the QC sample is not capable of representing analytical stability. 
For example, component formations due to other metabolic processes 
in in vivo generated samples may significantly affect the quantity of the 
analyte [9].
Several methods for analyzing metformin in plasma using high-
performance liquid chromatography (HPLC) have been reported. In a 
previous study, the development and validation of the determination 
of metformin by HPLC were only determined in spiked plasma, and 
no studies have evaluated ISS. Therefore, in this study, we sought to 
measure metformin levels and evaluate incurred sample stability 
in plasma samples from healthy subjects. HPLC was selected as the 
analytical method because it includes tools that are generally present 
in the laboratory; thus, methods can be applied for BE testing as well as 
other clinical trials. In this study, we used a photodiode array detector, 
which allowed for a quick and accurate analysis [10].
After validation of analysis method, we considered it necessary to 
further evaluate the stability of metformin HCl in the plasma of healthy 
subjects after administration of an 850-mg metformin tablet. We 
performed an ISS on six subjects by reanalyzing some of the samples 
that were around the Cmax and in the elimination phase. Blood sampling 
in the subjects was performed at up to 12 time points during a 12 h 
period.
METHODS
This research passed the ethical review of the Medical Research Ethics 
Committee of the Faculty of Medicine, Universitas Indonesia, with 
number 63/UN2.FI/ETIK/2017.
Solution preparation
Preparation of the metformin HCl solution for the calibration curve
A standard metformin HCl stock solution was prepared by dissolving 
10.0 mg into 10 mL of methanol. From the solution, 1 mL was further 
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diluted to 100 mL. From this dilute solution, methanol was added to 
obtain different concentrations of the calibration curve.
Preparation of the metformin HCl solution for quality control
A standard metformin HCl stock solution was prepared by dissolving 
10.0 mg into 10 mL of methanol. From this solution, 1 mL was further 
diluted to 100 mL. From this dilute solution, aquadest was added to 
obtain several concentrations of the QC sample.
Preparation of the atorvastatin solution as an internal standard
The stock solution was prepared by dissolving 10 mg in 100 mL of 
methanol followed by dilution at 1:100.
Experimental steps
Verification of the chromatographic conditions for metformin 
HCl analysis
The analytical method used HPLC method in conjunction with a 
photodiode array detector set at a wavelength of 234 nm. The separation 
used a C18 column (Waters, SunFire™ 5 μm; 250×4.6 mm). The mobile 
phase consists of 10 mM sodium dodecyl sulfate and 10 Mm of phosphate 
buffer in water-acetonitrile (60:40). The mobile phase was adjusted to 
pH 7.0 with 98% orthophosphoric acid; the column temperature was set 
to 40°C, and the flow rate was 1 mL/min over a 10-min analysis period.
Sample preparation from healthy subjects
Sampling procedure
Blood samples were taken at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, and 12 h. 
As much as 5 mL was taken at each time, after the healthy subjects were 
administered a tablet containing 850 mg metformin HCl. Blood was 
collected into a 5-mL vacuum tube containing a citrate anticoagulant.
Sample preparation
Sample preparation of metformin HCl in plasma was performed 
by protein precipitation. A 300 μL plasma aliquot containing a 
concentration of metformin HCl was added to the sample cup followed 
by the addition of atorvastatin (50.0 μL; 100 μg/mL) and 600 μL 
acetonitrile as a protein precipitator. The solution was then shaken and 
vortexed for 30 s to extract the metformin HCl from the plasma. The 
mixture was then centrifuged to precipitate proteins at 13,000 rpm for 
10 min. The supernatant was transferred into a vial. Then, as much as 
50.0 μL was injected into the HPLC system.
Partial validation of analytical method
The lower limit of quantitation (LLOQ)
The calibration curve of metformin HCl solution was prepared using 
concentrations of 12.5, 50, 100, 500, 1000, 2500, and 5000 ng/mL, and 
50.0 μL of atorvastatin (100 μg/mL). Each concentration was extracted 
as described above and aliquots (as much as 50 μL) were injected into 
the HPLC system.
Calibration curve
The calibration curve solution was prepared by diluting the 
standard metformin HCl 10 μg/mL solution with plasma to produce 
concentrations of 20, 50, 100, 250, 500, 1000, 2500, 3750, and 
5000 ng/mL. At each concentration, 50.0 μL of atorvastatin (100 μg/mL) 
was added and the solution was extracted according to the sample 
preparation method. Aliquots generated from each sample were then 
injected (as much as 50.0 μL) into the HPLC system under the selected 
chromatographic conditions.
Accuracy and precision
The plasma was prepared with metformin HCl at concentrations of 
the LLOQ and QC. Standard solution of metformin HCl 10 μg/mL was 
diluted with plasma to give the following concentrations:
a. QCH = 75%×ULOQ (5000 ng/mL)=3750 ng/mL
b. QCM = 50% the concentration range of the calibration curve= 
2500 ng/mL
c. QCL = 3×LLOQ concentration (12.5 ng/mL)=37.5 ng/mL
At each concentration, 50.0 μL atorvastatin (100 μg/mL) was added 
and the solution was extracted according to the sample preparation 
method. A total of 50.0 μL aliquots of each solution were then injected 
into the HPLC system.
Stability test
Stability of stock solutions of metformin HCl and atorvastatin
The metformin HCl stock solution in aquabidestilata was prepared 
at a concentration of 5000 ng/mL and the standard stock solution 
of atorvastatin was prepared at a concentration of 10 μg/mL. Stock 
solutions of metformin HCl and the atorvastatin were stored at room 
temperature for 0, 6, and 24 h as a short-term stability test. A portion 
of the solution was again stored at 4 °C (refrigerator) over a range of 
0, 7, 14, and 30 days as a long-term stability test. Each stock solution 
was then injected (as much as 50.0 μL) into the HPLC system.
Freeze and thaw stability
Plasma samples were subjected to three freeze-thaw cycles. Samples 
were then stored and frozen at a temperature −20°C in the freezer 
for 24 h, then discharged and melted at room temperature. Samples 
were then refrozen for 12 h. The analysis was performed on the 1st and 
3rd cycles. Samples were thawed first at room temperature and then 
added with 50.0 μL standard atorvastatin solution (100 μg/mL), then 
extracted as described for sample preparation. Aliquots (50.0 μL) were 
then injected as the supernatant for each concentration into the HPLC 
system.
Short-term stability of metformin HCl in plasma
Plasma samples were stored at room temperature for 0, 6, and 24 h. 
Thereafter, each concentration was added with 50.0 μL of standard 
atorvastatin solution (100 μg/mL), then extracted as in the sample 
preparation. Aliquots of each concentration were then injected (as 
much as 50.0 μL) into the HPLC system.
Long-term stability of metformin HCl in plasma
Plasma samples were stored at −20°C for a defined time period. On 
days 0, 7, and 14 at each sample concentration, 50.0 μL atorvastatin 
(100 μg/mL) was added, and the sample was extracted as in the sample 
preparation. Aliquots for each concentration were injected (as much as 
50 μL) into the HPLC system.
Post-preparation stability (autosampler)
Plasma samples were added with 50.0 μL atorvastatin (100 μg/mL), 
then extracted as in the sample preparation. Aliquots were stored on 
the autosampler at room temperature for 24 h and then analyzed at the 
0 and 24 h.
Pharmacokinetics parameter analysis of six healthy subjects in 
plasma
In this study, pharmacokinetic parameters were analyzed for six healthy 
subjects in plasma on days 0, 7, 14, and 30. For each subject, the average 
of AUC0-t, Cmax, tmax, and t1/2 was calculated.
ISS of metformin HCl in plasma
The ISS of metformin HCl in plasma was performed over a period of 
time to determine the stability of the analyte. The ISS was performed 
with plasma samples stored at −20°C for a defined time period. On days 
0, 7, 14, and 30, 50.0 μL atorvastatin (100 μg/mL) was added, and the 
sample was extracted as in the sample preparation. The supernatants 
from each concentration were then injected (as much as 50 μL) into the 
HPLC system. ISS was then analyzed in the Cmax and elimination phase 
for each healthy subject.
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RESULTS AND DISCUSSION
Validation of metformin HCl methods in plasma
LLOQ measurement
In this study, the measurement of the LLOQ value was done by making 
an analytical calibration curve with a concentration of 20 ng/mL, up 
to 5000 ng/mL. The concentration of 20 ng/mL becomes LLOQ, and 
the repetition of these concentrations was carried out for five replicas. 
The values of percentage difference and coefficient of variation (CV) at 
concentrations of 20 ng/mL still met the accuracy and precision criteria 
of ≤20%.
Results of the calibration curve
The calibration curve consisted of zero samples (plasma with internal 
standard) and non-zero plasma samples (plasma with analyte and 
internal standard) of 9 concentrations, namely, 20, 50, 100, 250, 500, 
1000, 2500, 3750, and 5000 ng/mL (Fig. 1).
Accuracy and precision
From the within-run accuracy measurements, we obtained a percentage 
difference value for the LLOQ concentrations ranging from −7.64% to 
+9.03%, while that for the QC concentrations ranged from −3.39% to 
+2.95%. For the measurement of within-run precision, we obtained a CV 
value of <6.68% for the LLOQ and QC concentrations. For the between-run 
measurement, we obtained an accuracy for the LLOQ concentration with 
the percentage difference range from −15.67% to +19.05%, while that for 
the concentration of QC had a percentage difference range from −5.56% 
to +13.43%. For the measurement of between-run precision, we obtained 
a CV value <7.76%. Both the within-run and between-run percentage 
difference and CV values met the precision and precision requirements.
Stability of stock solutions of metformin HCl and atorvastatin
The stability test of the metformin HCl atorvastatin stock solution 
met the requirement that the percentage difference value should not 
exceed ±2%.
Stability of freeze-thaw metformin HCl in plasma
The results we obtained for the percentage difference values for QCL 
ranged from −0.72% to +4.13%, while that for QCH ranged from 
−0.72% to −0.77%. The freeze-thaw stability test met the requirements 
that the percentage difference and CV values should not exceed ±15%.
Short-term stability of metformin HCl in plasma
Based on these data, the percentage difference after 24 h for the QCL 
concentrations ranged from −0.72% to +3.14%, while that for the QCH 
concentrations ranged from −0.30% to −0.78%. This indicates that 
plasma samples of metformin HCl can be stored at room temperature 
for at least 24 h as it met the stability requirements.
Long-term stability of metformin HCl in plasma
From the results obtained at −20°C, the percentage difference values 
on the 14th day of the QCL concentration ranged from 1.03% to 3.24%, 
while that at QCH concentrations ranged from−0.31% to −0.76%. For the 
results obtained at −80°C, the percentage difference value on the 14th day 
of the QCL concentration ranged from 0.71% to 3.52%, while that at 
QCH concentrations ranged from −0.27% to −0.83%. This indicates that 
plasma samples of metformin HCl are still stable and can be stored at 
−20°C or−80°C for at least of 14 days as it met the stability requirements.
Post-preparation stability (autosampler) of metformin HCl in 
plasma
Based on the data, the value of percentage difference after 24 h for QCL 
ranged from 2.08% to 4.41%, while that for QCH ranged from −0.29% 
to +0.09%. Thus, the extracted plasma can be stored in the autosampler 
for at least 24 h before because it met the requirements that the 
percentage difference value ≤15%.
Pharmacokinetic parameter analysis of six healthy subjects in 
plasma
The analysis of the pharmacokinetics parameters in plasma 
from six healthy subjects who administered 850 mg metformin 
hydrochloride tablets obtained median values as follows (Figs. 2-5): 
Fig. 1: Metformin HCl calibration curve
Fig. 2: Pharmacokinetic profiles of six healthy subjects in plasma 
day 0
Fig. 3: Pharmacokinetic profile of six healthy subjects in 7th-day 
plasma
Fig. 4: Pharmacokinetic profile of six healthy subjects in the  
14th-day plasma
Fig. 5: Pharmacokinetic profile of six healthy subjects in the  
30th-day plasma
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Day 0 Cmax=1724 ng/mL; tmax=3 h; t1/2=2 h; AUC0-t=8248 ng h/mL; 
AUC0-∞=8457 ng h/mL; day 7 Cmax=1649 ng/mL; tmax=3 h; t1/2=2 h; 
AUC0-t=7987 ng h/mL; AUC0-∞=8188 ng h/mL; day 14 Cmax=1568 ng/mL; 
tmax=3 h; t1/2=2 h; AUC0-t=7810 ng h/mL; AUC0-∞=8007 ng h/mL; and 
day 30 Cmax=1450 ng/mL; tmax=3 h; t1/2=2 h; AUC0-t=7584 ng h/mL; 
AUC0-∞=7796 ng h/mL.
The ISS of metformin HCl in plasma
The ISS of metformin HCl in plasma was performed over a period of time 
to determine the stability of the analyte. The ISS was done by storing 
the plasma at −20°C for a defined time period. On days 0, 7, 14, and 30, 
at each sample concentration, 50.0 μL atorvastatin (100 μg/mL) was 
added. The sample was then extracted as in the sample preparation. 
ISS data obtained can be seen in Table 1. Based on the calculation of 
ISS analysis, all subjects met the requirements that the percentage 
difference value should not be >20% of the mean in at least 67% or two-
thirds of the total sample conducted as stated in the EMEA Bioanalytical 
Guidelines (2011).
CONCLUSION
The incurred sample of metformin hydrochloride in plasma od six 
healthy subjects was stable until 30 days after administration of 850 mg 
HCl tablets.
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Table 1: Data of incurred sample stability of subjects
Subject Period Days
7 14 30
Subject 1 5 1.9699 8.1338 17.6180
6 4.8268 7.7860 17.2180
9 3.1591 7.8418 9.55000
Subject 2 5 4.5311 13.8201 19.2554
6 5.3822 9.2911 16.9648
9 5.3812 7.5837 18.4434
Subject 3 5 0.1345 8.8426 15.4791
6 4.5965 10.1975 16.4481
9 3.4614 3.4769 11.4038
Subject 4 5 4.6369 6.7828 12.8174
6 5.1418 8.6638 16.2470
9 3.5954 8.6945 15.8748
Subject 5 5 0.8373 7.3097 16.1559
6 4.9249 10.6615 14.1513
9 2.0786 10.0936 16.5275
Subject 6 6 4.2576 8.8480 16.3667
7 1.5022 7.7817 14.2778
9 4.5763 7.3055 9.6193
